Byeongsang Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Byeongsang Oh has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- David Rosenthal
Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215
1 shared publication - Jihun Kim
Master’s Program for Smart Agro, ICT Convergence Studies at Jeonju University, Jeonju, South Korea
1 shared publication - Josiah Poon
The University of Sydney, Sydney, NSW, Australia
1 shared publication - Weidong Lu
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States
1 shared publication Xiangji Huang
School of Computer Science, Central China Normal University, Wuhan, China ; School of Information Technology, York University, Toronto, ON, Canada
1 shared publication- Zhaohui Liang
Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2015
- Published by Wiley in The Scientific World Journal
- Vol. 2015 (1) , 460490
Bioinformatics/Medical Informatics in Traditional Medicine and Integrative Medicine
- 1 January 2015
- Published by Wiley in The Scientific World Journal
- Vol. 2015 (1) , 460490
Open AccessBioinformatics/Medical Informatics in Traditional Medicine and Integrative Medicine
- Open Access
- 22 January 2014
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2014 (1) , 865375
Anticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2‐targeting reagent lapatinib on cancer cells. Method. We selected six EGFR/ERBB2‐amplified cancer cell lines (OE19, NCI‐N87, OE33, ESO26, MKN7, and BT474) as an in vitro model and tested their sensitivity to DF alone and to DF in combination with the well‐known EGFR/ERBB2‐targeting reagent lapatinib. Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2‐amplified cancer cells in vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI‐N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.
- 22 January 2014
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2014 (1) , 865375
Open AccessAnticancer Effect of Fucoidan in Combination with Tyrosine Kinase Inhibitor Lapatinib
Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2‐targeting reagent lapatinib on cancer cells. Method. We selected six EGFR/ERBB2‐amplified cancer cell lines (OE19, NCI‐N87, OE33, ESO26, MKN7, and BT474) as an in vitro model and tested their sensitivity to DF alone and to DF in combination with the well‐known EGFR/ERBB2‐targeting reagent lapatinib. Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2‐amplified cancer cells in vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI‐N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.